NYSE · Healthcare
Evommune, Inc. (EVMN)
As-reported financials and recent SEC filings for Evommune, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$13.0M
Net income
$-68.9M
Net margin
—
Diluted EPS
$-11.22
ROE
-33.5%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2025 |
|---|---|---|
| Revenue | $13.0M | $7.0M |
| Gross profit | — | — |
| Operating income | $-81.1M | $-70.0M |
| Net income | $-68.9M | $-66.8M |
| Diluted EPS | $-11.22 | $-11.32 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
424B32026-06-29
View on EDGAR →8-K2026-06-29
View on EDGAR →42026-06-24
View on EDGAR →42026-06-24
View on EDGAR →42026-06-24
View on EDGAR →1442026-06-22
View on EDGAR →42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →Largest Healthcare peers
Go deeper on EVMN
Search Evommune, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.